Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420) announced a licensing agreement with Shanghai ScienPharm, obtaining rights to the latter’s generic version of Eisai’s Myonal (eperisone) for RMB 10.5 million (USD 1.5 million). The centrally acting muscle relaxant, used for cervicobrachial syndrome, periarthritis of the shoulder, low back pain, and spastic paralysis, is currently under marketing review in China, positioning Shyndec to capture share in the RMB 2+ billion muscle relaxant market upon approval.
Pain management portfolio expansion – complements existing NSAIDs and neuropathic pain assets; leverages hospital rehabilitation medicine relationships
ScienPharm Position
Development-to-licensing model – monetizes ANDA filing without building commercial infrastructure
Commercial Timeline: NMPA approval expected H2 2026; Shyndec sales force deployment to orthopedics, rehabilitation, and pain management departments
Revenue Potential: Peak sales RMB 80–120 million annually assuming 10–15% market share in eperisone segment; NRDL inclusion 2027 critical for volume expansion
Forward‑Looking Statements This brief contains forward‑looking statements regarding NMPA approval timelines, generic pricing dynamics, and market penetration for eperisone in China. Actual results may differ due to regulatory review delays, competitive entry from other eperisone generics, and reimbursement negotiations.-Fineline Info & Tech
By Fineline Cube